Hormone receptor positive HER2 negative breast cancer
Not recruitingStudy on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors
Study on Pembrolizumab and Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer in Patients Resistant to CDK 4/6 Inhibitors
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:Pembrolizumab
Spain- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Solti Group













